

Set Name Query

side by side

Hit Count Set Name

result set

DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=OR

<u>L14</u>	creatine and (creatine adj1 analog\$)	55	<u>L14</u>
<u>L13</u>	L12 and cyclocreatine	3	<u>L13</u>
<u>L12</u>	l11 and fatigue	49	<u>L12</u>
<u>L11</u>	(creatine adj1 phosphate) or cyclocreatine	667	<u>L11</u>
<u>L10</u>	l9 and fatigue	49	<u>L10</u>
<u>L9</u>	(creatine adj1 phosphate)	656	<u>L9</u>
<u>L8</u>	l7 and fatigue	24	<u>L8</u>
<u>L7</u>	creatine adj2 analog\$	60	<u>L7</u>
<u>L6</u>	L4 and (fatigue)	110	<u>L6</u>
<u>L5</u>	L4 and (fatifue)	0	<u>L5</u>
<u>L4</u>	l1 and (drink or beverage or supplement or medication)	375	<u>L4</u>
<u>L3</u>	l1 and (increase adj muscle adj3 mass)	11	<u>L3</u>
<u>L2</u>	l1 and (increase adj muscle adj3 volume)	0	<u>L2</u>
<u>L1</u>	creatine and (fatigue or muscle)	1215	<u>L1</u>

END OF SEARCH HISTORY

updated
1/3/02

WEST

Generate Collection

Print

L7: Entry 41 of 60

File: EPAB

Apr 17, 1997

PUB-NO: WO009713507A1

DOCUMENT-IDENTIFIER: WO 9713507 A1

TITLE: USE OF CREATINE ANALOGUES FOR THE TREATMENT OF DISORDERS OF GLUCOSE METABOLISM

PUBN-DATE: April 17, 1997

INVENTOR-INFORMATION:

NAME

COUNTRY

KADDURAH-DAOUK, RIMA

TEICHER, BEVERLY A

ASSIGNEE-INFORMATION:

NAME

COUNTRY

AVICENA GROUP INC

US

DANA FARBER CANCER INST INC

US

APPL-NO: US09616365

APPL-DATE: October 11, 1996

PRIORITY-DATA: US54089495A (October 11, 1995)

INT-CL (IPC): A61 K 31/195

EUR-CL (EPC): A61K031/195; A61K031/195, A61K031/395 , A61K031/40 , A61K031/415 ,
A61K031/415 , A61K031/66 , A61K031/66 , A61K031/66 , A61K031/675

ABSTRACT:

CHG DATE=19990617 STATUS=O>The present invention relates to the use of creatine compounds including cyclocreatine and creatine phosphate for treating or preventing a metabolic disorder consisting of hyperglycemia, insulin dependent diabetes mellitus, impaired glucose tolerance, hyperinsulinemia, insulin insensitivity, diabetes related diseases in a patient experiencing said disorder. The creatine compounds which can be used in the present method include: (1) analogues of creatine which can act as substrates or substrate analogues for the enzyme creatine kinase; (2) compounds which can act as activators or inhibitors of creatine kinase; (3) compounds which can modulate the creatine transporter; (4) N-phosphocreatine analogues bearing transferable or non-transferable moieties which mimic the N-phosphoryl group; (5) compounds which modify the association of creatine kinase with other cellular components.

WEST

Generate Collection

Print

L7: Entry 55 of 60

File: DWPI

Nov 24, 1994

DERWENT-ACC-NO: 1995-006328
DERWENT-WEEK: 199501
COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Treatment of body parts susceptible to ischaemia - comprises administratio n of
creatine analogue

INVENTOR: ELGEBALY, S A; KADDURAH-DAOUK, R

PATENT-ASSIGNEE:

ASSIGNEE

CODE

AMIRA INC

AMIRN

HARTFORD HOSPITAL

HARTN

PRIORITY-DATA: 1994US-0243628 (May 16, 1994), 1993US-0061677 (May 14, 1993)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9426261 A1	November 24, 1994	E	056	A61K031/195
AU 9469502 A	December 12, 1994		000	A61K031/195

DESIGNATED-STATES: AU CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

CITED-DOCUMENTS:01Jnl.Ref; EP 230037 ; US 3843798 ; US 5091404 ; US 5190976 ; US 5290766 ; WO 9107954 ; WO 9112800

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
WO 9426261A1	May 16, 1994	1994WO-US05425	
AU 9469502A	May 16, 1994	1994AU-0069502	
AU 9469502A		WO 9426261	Based on

INT-CL (IPC): A61K 31/195; A61K 31/395; A61K 31/40; A61K 31/675; A61K 31/685

ABSTRACTED-PUB-NO: WO 9426261A

BASIC-ABSTRACT:

Treating a body part susceptible to ischaemia comprises admin. of a creatine analogue provided that the creatine analogue is not creatine phosphate or cyclocreatine when the analogue is administered prior to ischaemia. Also claimed is a compsn. for treating an organ intended for transplantation comprising a creatine analogue in an organ treatment soln.

USE - The creatine analogues can be used for treating ischaemia and ischaemia-associated diseases or conditions such as congestive heart failure and angina. The cpds. can be used for treating tissues such as muscle tissue, connective tissue, epithelial tissue, nervous tissue or cardiac tissue or organs such as reproductive organs, respiratory organs, digestive organs, excretatory organs, urinary organs, sensory organs and skeletal muscle organs (pref. the kidney, heart, pancreas, liver, gall bladder, brain, spleen or spinal cord) for ischaemia. The compsn. can be used for preserving kidneys, heart, pancreas, liver or lung for transplantation.

CHOSEN-DRAWING: Dwg.0/21

WEST



Generate Collection

Print

L6: Entry 109 of 110

File: DWPI

Sep 3, 1996

DERWENT-ACC-NO: 1996-449902
DERWENT-WEEK: 199645
COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Creatine drink prodn. for use as health drink - comprises adding crystalline power of creatine to water, adding flavour and sterilising

PATENT-ASSIGNEE:

ASSIGNEE

CODE

SUEOKA H

SUEOI

PRIORITY-DATA: 1995JP-0087771 (February 20, 1995)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
JP 08224073 A	September 3, 1996		004	A23L002/52

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
JP08224073A	February 20, 1995	1995JP-0087771	

INT-CL (IPC): A23 L 2/52; A61 K 31/195

ABSTRACTED-PUB-NO: JP08224073A

BASIC-ABSTRACT:

Creatine drink is produced by adding 1-3 g crystalline powder of creatine into 100 cc slightly alkaline and warm water with stirring to give an aq. soln., adding a nutrition or flavour as additive to the latter, and then sterilising the resulting mixt.. The pref. additives are fruit sugars, amino acids, Ca, Mg and/or vitamins. The drink is pref. placed in a vessel such as capsule, can or bottle. Water is adjusted at pH 7-10 and a temp. of 20-90 deg.C. The aq. mixt. is sterilised by heating at 60-105 deg. C. or by passing through a filter of 0.2 psim or smaller pore size. USE/ADVANTAGE - The drinks include health drink, tonic drink and nutrition drink. Creatine is effective in recover of muscular fatigue, but it in a neutral or acidic soln. is readily converted into creatinine. Creatinine has no action in muscle and is readily excreted in urine. Creatine, however, is stable in the drinks. In an example, distilled water (amt. corresp. to 1 batch) is adjusted at pH 7-10 (pref. pH 9 or lower) with an alkaline soln. and warmed up to 20-99 deg. C. There is added 1-3 wt. part of creatine powder for 100 wt. part water with stirring to give a soln. of which the taste is improved with a flavour for drinking. There is further added a nutrition source, e.g. fruit sugars, amino acids, minerals (Ca, Mg), vitamins. The mixt. is sterilized by heating or filtration as mentioned above and placed in bottles or cans of 100-150 cc vol.. The creatine content is adjusted so as to be 1-3 g/100 cc or 1.5-4.5 g/150 cc.

CHOSEN-DRAWING: Dwg. 0/0

TITLE-TERMS: CREATINE DRINK PRODUCE HEALTH DRINK COMPRISE ADD CRYSTAL POWER CREATINE
WATER ADD FLAVOUR STERILE

DERWENT-CLASS: B05 D13 E16

CPI-CODES: B03-L; B04-A08C2; B04-A10G; B04-D01; B05-A01B; B10-A17; B10-B02; B14-J05;
D03-H01G; D03-H01T; E10-A17B;

WEST**End of Result Set**☐ **Generate Collection** **Print**

L6: Entry 110 of 110

File: DWPI

Aug 18, 1994

DERWENT-ACC-NO: 1994-279366

DERWENT-WEEK: 199434

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Compsn. comprising sugar and amidino-aminoacid (deriv.) - useful in treatment of multiple sclerosis, mood disorders, dementias or chronic fatigue syndrome

INVENTOR: JENNINGS, S A

PATENT-ASSIGNEE:

ASSIGNEE

CODE

JENNINGS S A

JENNI

PRIORITY-DATA: 1993GB-0025374 (December 10, 1993), 1993GB-0002070 (February 3, 1993), 1993GB-0020187 (September 30, 1993)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9417794 A1	August 18, 1994	E	011	A61K031/195
AU 9458903 A	August 29, 1994		000	A61K031/195
ZA 9400634 A	November 30, 1994		009	A61K000/00

DESIGNATED-STATES: AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN AT BE CH DE DK ES FR GB GR IE IT LU MC NL OA PT SE

CITED-DOCUMENTS:EP 339814; EP 370994 ; GB 1208398

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
WO 9417794A1	January 31, 1994	1994WO-GB00181	
AU 9458903A	January 31, 1994	1994AU-0058903	
AU 9458903A	January 31, 1994	1994WO-GB00181	
AU 9458903A		WO 9417794	Based on
ZA 9400634A	January 31, 1994	1994ZA-0000634	

INT-CL (IPC): A61K 0/00; A61K 31/195

ABSTRACTED-PUB-NO: WO 9417794A

BASIC-ABSTRACT:

Compsn. comprises (a) a glycine deriv. of formula (I) $X'N=C(NX_2Y)-NX_3-CX_4X_5-CO_2H$ or its salt and (b) 2-98% (by wt. of deriv. (I)) of a sugar. $X_1-X_5 = H$ or lower alkyl; $Y = H$, lower alkyl or H_2PO_3 (or a substd. variant of this).

Pref., $X = Me$ and $Y = H_2PO_3$.

USE/ADVANTAGE - The compsns. can be used as metabolic supplements to enhance tissue formation, in treatment of wasting diseases such as multiple sclerosis and to enhance cardiac tissue formation. The compsns. can also be used to treat mood disorders (e.g., depression), schizophrenia, dementias (e.g., Alzheimer's disease) anxiety, or obsessive

compulsive disorders) or chronic fatigue syndrome. The compsns. can be administered in powder, tablet or soln. form. The compsns. contain naturally occurring constituents and have a pleasant taste:

CHOSEN-DRAWING: Dwg.0/0

TITLE-TERMS: COMPOSITION COMPRISE SUGAR AMIDINO AMINOACID DERIVATIVE USEFUL TREAT MULTIPLE SCLEROSIS MOOD DISORDER CHRONIC FATIGUE SYNDROME

ADDL-INDEXING-TERMS:
CREATINE

DERWENT-CLASS: B05

CPI-CODES: B04-D01; B05-B01L; B10-A17; B14-E11; B14-J01;

CHEMICAL-CODES:

Chemical Indexing M2 *01*

Fragmentation Code

B415 B701 B712 B720 B731 B793 B799 B815 B831 J0
J011 J1 J171 L250 M210 M211 M212 M213 M214 M215
M216 M220 M221 M222 M223 M224 M225 M226 M231 M232
M233 M273 M280 M281 M282 M283 M311 M312 M313 M314
M315 M316 M321 M331 M333 M340 M342 M349 M381 M391
M411 M416 M431 M510 M520 M530 M540 M620 M630 M640
M650 M782 M903 M904 P446 P448 P517 P520 P522

Markush Compounds

199434-30301-M

Chemical Indexing M2 *02*

Fragmentation Code

H4 H405 H484 H8 J5 J581 K0 L8 L818 L821
L831 M280 M311 M314 M321 M332 M342 M344 M349 M381
M392 M416 M431 M620 M782 M903 M904 M910 P446 P448
P517 P520 P522

Specfic Compounds

00134M

Registry Numbers

0134U

Chemical Indexing M2 *03*

Fragmentation Code

H4 H405 H484 H8 J4 J471 K0 L8 L814 L821
L831 M280 M315 M321 M332 M344 M349 M381 M391 M416
M431 M620 M782 M903 M904 M910 P446 P448 P517 P520
P522

Specfic Compounds

00038M

Registry Numbers

0038U

Chemical Indexing M2 *04*

Fragmentation Code

F012 F013 F014 F015 F016 F123 H4 H405 H423 H484
H5 H521 H8 J4 J471 K0 L8 L814 L819 L822
L831 M280 M311 M315 M321 M332 M342 M344 M349 M373
M381 M391 M413 M431 M510 M521 M530 M540 M782 M903

M904 M910 P446 P448 P517 P520 P522

Specific Compounds

00292M

Registry Numbers

0292U

Chemical Indexing M6 *05*

Fragmentation Code

M903 P446 P448 P517 P520 P522 Q222 R036 R111 R280

UNLINKED-DERWENT-REGISTRY-NUMBERS: 0038U; 0134U ; 0292U

SECONDARY-ACC-NO:

CPI Secondary Accession Numbers: C1994-127451